dc.creator | Nicolaides N.C., Skyrla E., Vlachakis D., Psarra A.-M.G., Moutsatsou P., Sertedaki A., Kossida S., Charmandari E. | en |
dc.date.accessioned | 2023-01-31T09:40:10Z | |
dc.date.available | 2023-01-31T09:40:10Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1111/eci.12563 | |
dc.identifier.issn | 00142972 | |
dc.identifier.uri | http://hdl.handle.net/11615/77169 | |
dc.description.abstract | Background: Chrousos syndrome is a rare pathologic condition characterized by generalized, partial resistance of target tissues to glucocorticoids and caused by inactivating mutations of the human glucocorticoid receptor (hGR) gene. A novel case of Chrousos syndrome has been reported in a patient with adrenal incidentaloma, who harboured a heterozygous point mutation in the hGR gene, which resulted in threonine (T) to isoleucine (I) substitution at amino acid position 556 in the ligand-binding domain of the receptor. Objective: To delineate the molecular mechanisms through which the mutant receptor hGRαT556I causes Chrousos syndrome. Design and Results: Compared with the wild-type receptor, the mutant receptor hGRαT556I demonstrated 50% reduction in its ability to transactivate glucocorticoid-responsive genes and in the affinity for the ligand, 30% increase in the ability to transrepress the nuclear factor-κB-target genes and a 3,4-fold delay in the cytoplasmic-to-nuclear translocation. The mutant receptor hGRαT556I did not exert a dominant negative effect upon the hGRα-mediated transcriptional activity; it preserved its ability to bind to DNA and interacted with the glucocorticoid receptor-interacting protein 1 coactivator mostly through its activation function-1 domain. Structural biology studies revealed that the T556I mutation caused disruption of the hydrogen bond formed by the T556 with the =O group of P637 backbone, which resulted in a significant relocation of the P637-bearing loop. This conformational alteration affected the local 3D arrangement of the receptor and hence the electrostatic surface of the region. Conclusions: The hGRαT556I causes Chrousos syndrome by impairing multiple steps of the glucocorticoid signal transduction pathway. © 2016 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. | en |
dc.language.iso | en | en |
dc.source | European Journal of Clinical Investigation | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955181268&doi=10.1111%2feci.12563&partnerID=40&md5=d473e0e9cf41453da5181e975edf3335 | |
dc.subject | glucocorticoid receptor alpha | en |
dc.subject | immunoglobulin enhancer binding protein | en |
dc.subject | isoleucine | en |
dc.subject | nuclear receptor coactivator 2 | en |
dc.subject | threonine | en |
dc.subject | dexamethasone | en |
dc.subject | glucocorticoid | en |
dc.subject | glucocorticoid receptor | en |
dc.subject | glucocorticoid receptor alpha | en |
dc.subject | NCOA2 protein, human | en |
dc.subject | nuclear receptor coactivator 2 | en |
dc.subject | adrenal incidentaloma | en |
dc.subject | amino acid substitution | en |
dc.subject | animal cell | en |
dc.subject | Article | en |
dc.subject | Chrousos syndrome | en |
dc.subject | conformational transition | en |
dc.subject | controlled study | en |
dc.subject | cytoplasm | en |
dc.subject | gene repression | en |
dc.subject | genetic disorder | en |
dc.subject | genetic transcription | en |
dc.subject | glucocorticoid responsive gene | en |
dc.subject | heterozygosity | en |
dc.subject | hGRalpha gene | en |
dc.subject | hormone responsive element | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | hydrogen bond | en |
dc.subject | mutant | en |
dc.subject | nonhuman | en |
dc.subject | nuclear localization signal | en |
dc.subject | point mutation | en |
dc.subject | priority journal | en |
dc.subject | protein DNA binding | en |
dc.subject | protein domain | en |
dc.subject | receptor gene | en |
dc.subject | transactivation | en |
dc.subject | wild type | en |
dc.subject | animal | en |
dc.subject | Chlorocebus aethiops | en |
dc.subject | COS cell line | en |
dc.subject | deficiency | en |
dc.subject | genetics | en |
dc.subject | HCT 116 cell line | en |
dc.subject | HeLa cell line | en |
dc.subject | inborn error of metabolism | en |
dc.subject | metabolism | en |
dc.subject | signal transduction | en |
dc.subject | Western blotting | en |
dc.subject | Animals | en |
dc.subject | Blotting, Western | en |
dc.subject | Cercopithecus aethiops | en |
dc.subject | COS Cells | en |
dc.subject | Dexamethasone | en |
dc.subject | Glucocorticoids | en |
dc.subject | HCT116 Cells | en |
dc.subject | HeLa Cells | en |
dc.subject | Humans | en |
dc.subject | Metabolism, Inborn Errors | en |
dc.subject | Nuclear Receptor Coactivator 2 | en |
dc.subject | Point Mutation | en |
dc.subject | Receptors, Glucocorticoid | en |
dc.subject | Signal Transduction | en |
dc.subject | Blackwell Publishing Ltd | en |
dc.title | Functional characterization of the hGRαT556I causing Chrousos syndrome | en |
dc.type | journalArticle | en |